PFIZER

Stocks fell on Thursday due to profit-taking in financials, a drag from the health-care sector and a bearish broker comment on 3M Co. Investors were also unsettled the the Federal Reserve's move to inject $1 trillion into the financial system could stir inflation in the long term.

Pfizer Inc may have to shed some of its animal-health business so that it can gain antitrust clearance for its planned purchase of Wyeth , the Wall Street Journal cited a Pfizer executive as saying on Wednesday.

Pfizer Inc, the world's largest drugmaker, launched a $13.5 billion debt sale in five parts on Tuesday, said IFR.

It is buying up less than half of Genentech Inc for a whopping $46.8 billion, but Switzerland's Roche Holding AG may have clinched the best of this year's three big drug deals.

A study of Pfizer Inc's Sutent was halted early after the medicine delayed progression of a rare form of pancreatic cancer affecting tens of thousands of people globally, including Apple Inc CEO Steve Jobs.

U.S. stocks fell in choppy trade and the Nasdaq slid to a fresh 6 and 1/2-year low on Monday as shares of the biggest drugmakers fell after Merck's proposed a $41 billion takeover of Schering-Plough .

U.S. stocks fell in choppy trade and the Nasdaq slid to a fresh 6 and 1/2-year low on Monday as shares of the biggest drugmakers fell after Merck's proposed a $41 billion takeover of Schering-Plough .

U.S. stocks fell in choppy trade and the Nasdaq slid to a fresh 6 and 1/2-year low on Monday as shares of the biggest drugmakers fell after Merck's proposed a $41 billion takeover of Schering-Plough .

U.S. stocks fell in choppy trade and the Nasdaq slid to a fresh 6 and 1/2-year low on Monday as shares of the biggest drugmakers fell after Merck's proposed a $41 billion takeover of Schering-Plough .

U.S. stocks fell in choppy trade and the Nasdaq slid to a fresh 6 and 1/2-year low on Monday as shares of the biggest drugmakers fell after Merck's proposed a $41 billion takeover of Schering-Plough .

Stocks fell in choppy trade on Monday as gains in the energy and banking sectors were more than offset by a drop in pharmaceuticals after Merck's proposed $41 billion takeover of Schering-Plough .

The Dow industrials and the S&P rose modestly while the Nasdaq dipped in choppy trade on Monday as gains by the energy and banking sectors were offset by a drop in pharmaceuticals after Merck's proposed $41 billion takeover of Schering-Plough .

The Dow industrials and the S&P rose modestly while the Nasdaq dipped in choppy trade on Monday as gains by the energy and banking sectors were offset by a drop in pharmaceuticals after Merck's proposed $41 billion takeover of Schering-Plough .

Pfizer Inc, the world's top drug maker, and French firm Sanofi-Aventis are in the race to buy a stake in Indian Wockhardt Ltd's biotechnology business, the Economic Times reported on Friday.

Goldman Sachs reinstated coverage of Pfizer Inc with a buy rating and added the stock to the conviction buy list, saying the world's biggest drugmaker was severely undervalued after its proposed acquisition of smaller rival Wyeth.

Pfizer Inc has agreed to license an array of generic pills and injectable medicines from India's Aurobindo Pharma Ltd as the world's largest drugmaker looks to off-patent medicines for growth.

Looking ahead, the chairman of Swiss pharmaceuticals company Roche Holding said Friday it expects to have financing ready when its needed in the company's hostile takeover bid for U.S.-based Genentech.

Caterpillar Inc., Sprint Nextel Corp., Home Depot, Pfizer Inc., General Motors, ING Groep NV and Royal Phillips Electronics NY announced a combined 69,000 job cuts on Monday.

Pharmaceuticals giant Pfizer Inc will acquire Wyeth in a $68 billion cash and stock deal -- the biggest U.S. merger in three years -- to create a diverse health products company which executives hope will deliver stable growth to investors, the companies said on Monday.

Drugmakers Pfizer and Wyeth are close to sealing a deal worth $68 billion in a cash-and-stock deal that could be announced before the markets open Monday, according to reports.

Pfizer Inc. is in talks to buy Wyeth in a deal potentially worth more than $60 billion, according to a report. The companies have held discussions for several months but the deal wasn't imminent. Talks are specially fragile and could collapse due to the volatility in the market and the uncertainty in the economy.